Non-small Cell Lung Cancer: Current Therapies and New Targeted Treatments

Conventional lung cancer treatments were once limited to surgery, radiation, and chemotherapy. However, gefitinib, a targeted drug, was launched in 2004, and the situation changed. Cancer cases that were highly responsive to gefitinib were later discovered to have epithelial growth factor receptor (...

全面介紹

Saved in:

書目詳細資料
格式:	Online
語言:	英语
出版:	MDPI - Multidisciplinary Digital Publishing Institute 2022
主題:	non-small cell lung cancer previously treated patients phase I/II trial chemotherapy docetaxel S-1 immunotherapy rechallenge retrospective analysis pulmonary pleomorphic carcinoma prognostic factor glucose transporter 1 lung cancer multiple cancers metastasis sequencing mutation genomic diagnosis FDG-PET immune checkpoint inhibitor PD-1 prognosis RAD51B methylation PD-L1 expression predictive biomarker PD-1 blockade interstitial lung disease pulmonary fibrosis radiology and other imaging non-small-cell lung cancer epidermal growth factor receptor tyrosine kinase inhibitors TP53 mutations responsiveness targeted therapy network meta-analysis stage IIIA-N2 surgery immune checkpoint inhibitors biomarker nonsmall cell lung cancer HIP1R PD-L1 RUNX1 methylation survival EGFR-TKI T790M osimertinib immune-related adverse events endocrine disorders tumor-bearing patients PD-1 inhibitors PD-L1 inhibitors meta-analysis nivolumab Expanded Access Program real-world data daily practice prognostic factors NSCLC KRAS DNA polymerase beta platinum-based first-line adjuvant chemotherapy β-catenin lung neoplasms nucleotide-diphosphate kinase recurrence unresectable salvage surgery oligometastasis thema EDItEUR::M Medicine and Nursing
在線閱讀:	ONIX_20220111_9783036501307_883
標簽:	添加標簽沒有標簽, 成為第一個標記此記錄!

成為第一個發表評論!

Non-small Cell Lung Cancer: Current Therapies and New Targeted Treatments

相似書籍